Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

April 30, 2017

Study Completion Date

September 10, 2018

Conditions
Procedural Sedation
Interventions
DEVICE

Dexmedetomidine

A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.

Trial Locations (1)

20521

Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital, Turku

All Listed Sponsors
collaborator

University of Turku

OTHER

lead

Turku University Hospital

OTHER_GOV

NCT02955732 - Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients | Biotech Hunter | Biotech Hunter